{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:22:33Z","timestamp":1793852553815,"version":"4.6.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anaesthesist"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00101-020-00839-x","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T15:31:30Z","timestamp":1600270290000},"page":"751-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kommentar zur Leitlinie der European Malignant Hyperthermia Group zur Verf\u00fcgbarkeit von Dantrolen f\u00fcr die Behandlung der Malignen Hyperthermie","Comments on the guidelines of the European Malignant Hyperthermia Group on the availability of dantrolene for the management of malignant hyperthermia crises"],"prefix":"10.1007","volume":"69","author":[{"given":"B.","family":"Bastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heiderich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"R\u00fcffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"839_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.04.089","author":"KPE Glahn","year":"2020","unstructured":"Glahn\u00a0KPE, Bendixen\u00a0D, Girard\u00a0T, Hopkins\u00a0PM, Johannsen\u00a0S, R\u00fcffert\u00a0H, Snoeck\u00a0MM, Urwyler\u00a0A (2020) Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. https:\/\/doi.org\/10.1016\/j.bja.2020.04.089","journal-title":"Br J Anaesth"},{"key":"839_CR2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins\u00a0PM, R\u00fcffert\u00a0H, Snoeck\u00a0MM, Girard\u00a0T, Glahn\u00a0KPE, Ellis\u00a0FR, M\u00fcller\u00a0CR, Urwyler\u00a0A, Bandschapp\u00a0O, Gillies\u00a0R, Glauber\u00a0V, Heytens\u00a0L, Islander\u00a0G, Klingler\u00a0W, Kraft\u00a0B, Krivosic-Horber\u00a0R, Pollock\u00a0N, Schuster\u00a0F, Silva\u00a0H, Sorrentino\u00a0V, Street\u00a0N, Tegazzin\u00a0V, Tzanova\u00a0I (2015) European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 115:531\u2013539","journal-title":"Br J Anaesth"},{"key":"839_CR3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/bja\/aeq243","volume":"105","author":"KPE Glahn","year":"2010","unstructured":"Glahn\u00a0KPE, Ellis\u00a0FR, Halsall\u00a0PJ, M\u00fcller\u00a0CR, Snoeck\u00a0MMJ, Urwyler\u00a0A, Wappler\u00a0F (2010) Recognizing and managing a\u00a0malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 105:417\u2013420","journal-title":"Br J Anaesth"},{"key":"839_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/ALN.0000000000002813","volume":"131","author":"CA Ibarra Moreno","year":"2019","unstructured":"Ibarra Moreno\u00a0CA, Hu\u00a0S, Kraeva\u00a0N, Schuster\u00a0F, Johannsen\u00a0S, Rueffert\u00a0H, Klingler\u00a0W, Heytens\u00a0L, Riazi\u00a0S (2019) An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology 131:983\u2013991","journal-title":"Anesthesiology"},{"key":"839_CR5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00101-014-2351-6","volume":"63","author":"S Wolak","year":"2014","unstructured":"Wolak\u00a0S, R\u00fccker\u00a0B, Kohlschmidt\u00a0N, Doetsch\u00a0S, Bartsch\u00a0O, Zechner\u00a0U, Tzanova\u00a0I (2014) Homozygote und \u201ecompound\u201c-heterozygote RYR1-Mutationen: Neue Erkenntnisse zu Pr\u00e4valenz und Penetranz der malignen Hyperthermie. Anaesthesist 63:643\u2013650","journal-title":"Anaesthesist"}],"container-title":["Der Anaesthesist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-020-00839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00101-020-00839-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-020-00839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T23:24:27Z","timestamp":1631748267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00101-020-00839-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s00101-020-00839-x","relation":{},"ISSN":["0003-2417","1432-055X"],"issn-type":[{"value":"0003-2417","type":"print"},{"value":"1432-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"16 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W. Klingler gibt an, dass die MH-Hotline von der Firma Norgine (Wettenberg, Deutschland) finanziell unterst\u00fctzt wird. B.\u00a0Bastian, S.\u00a0Heiderich, F.\u00a0Schuster, S.\u00a0Johannsen und H.\u00a0R\u00fcffert geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}